A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 12, 2015, Pages 1467-1469

  Kao, Steven C ^a,b,c   Fulham, Michael ^c,d   Wong, Kirby ^d   Cooper, Wendy ^c,d,e   Brahmbhatt, Himanshu ^f   MacDiarmid, Jennifer ^f   Pattison, Scott ^f   Sagong, Jin Og ^a   Huynh, Yennie ^b   Leslie, Felicity ^b   Pavlakis, Nick ^c,g   Clarke, Stephen ^c,g   Boyer, Michael ^a,c   Reid, Glen ^b,c   Van Zandwijk, Nico ^b,c  

^a Chris O'Brien Lifehouse   (Australia)

^b Asbestos and Dust Diseases Research Institute   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f EnGeneIC Ltd   (Australia)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; INTERLEUKIN 6; MICRORNA; PEMETREXED; TARGOMIR; UNCLASSIFIED DRUG;

ADULT; CANCER CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; CHILL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG FEVER; DRUG INDUCED HEADACHE; HUMAN; LETTER; LUNG FUNCTION TEST; MALE; METABOLISM; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OTOTOXICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PLEURODESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; COMPUTER ASSISTED TOMOGRAPHY; LUNG; LUNG NEOPLASMS; MESOTHELIOMA; RADIOGRAPHY; TREATMENT OUTCOME;

HUMANS; LUNG; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MICRORNAS; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84938496867     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201503-0461LE     Document Type: Letter

References (6)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
2. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23:6881-6889.
3. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011;80:193-208.
4. Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJ, Vallely MP, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol 2013;24:3128-3135.
5. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, Haasdyk JE, Dickson KA, Brahmbhatt VN, Pattison ST, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 2007;11: 431-445.
6. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol 2011;6:598-601.